TrialDiabetes, obesity & metabolism2020

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.

Eiichi Araki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.